

REVIEW ARTICLE

Part III. Analysis of data gaps pertaining to enterotoxigenic *Escherichia coli* infections in low and medium human development index countries, 1984–2005

S. K. GUPTA^{1*}, J. KECK², P. K. RAM³, J. A. CRUMP¹, M. A. MILLER⁴
AND E. D. MINTZ¹

¹ Enteric Diseases Epidemiology Branch, National Center for Zoonotic, Vectorborne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

² University of Minnesota Medical School, Minneapolis, MN, USA

³ School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA

⁴ Fogarty International Center, National Institutes of Health, Bethesda, MD, USA

(Accepted 30 June 2007; first published online 9 August 2007)

SUMMARY

Enterotoxigenic *Escherichia coli* (ETEC) is a common cause of profuse watery diarrhoea in the developing world, often leading to severe dehydration or death. We found only 15 population-based studies in low and medium human development index (HDI) countries from 1984 to 2005 that evaluate disease incidence. Reported incidence ranged from 39 to 4460 infections/1000 persons per year. The peak incidence of ETEC appeared to occur between ages 6 and 18 months. A median of 14% (range 2–36%) of diarrhoeal specimens were positive for ETEC in 19 facility- and population-based studies conducted in all age groups and 13% (range 3–39%) in 51 studies conducted in children only. Heat-labile toxin (LT)-ETEC is thought to be less likely to cause disease than heat-stable toxin (ST)-ETEC or LT/ST-ETEC. Because population-based studies involve enhanced clinical management of patients and facility-based studies include only the most severe illnesses, reliable data on complications and mortality from ETEC infections was unavailable. To reduce gaps in the current understanding of ETEC incidence, complications and mortality, large population-based studies combined with facility-based studies covering a majority of the corresponding population are needed, especially in low-HDI countries. Moreover, a standard molecular definition of ETEC infection is needed to be able to compare results across study sites.

INTRODUCTION

Enterotoxigenic *Escherichia coli* (ETEC) causes an estimated 840 million gastrointestinal infections [1], and about 380 000 deaths worldwide each year [2]. Infection with ETEC leads to profuse watery

diarrhoea, and can be confused with cholera. ETEC is primarily spread through food or water contaminated with human waste, and is a frequent cause of outbreaks of diarrhoea. Prevention and control of ETEC infections is through the provision of safe food, water and sanitation, which has proved difficult to achieve on a large scale in the developing world. Currently no effective vaccine exists.

To identify contemporary gaps in the understanding of the global epidemiology of ETEC infection, we conducted a review of the recent scientific literature. We summarize below recent available data on

* Author for correspondence: S. K. Gupta, M.D., CDC Global AIDS Program Central America and Panama, Apartado Postal 3013, Correo Nacional, Tegucigalpa, Honduras, Central America. (Email: scg7@cdc.gov)

This is the third of three papers, appearing in successive issues of the Journal, reviewing the analysis of data gaps pertaining to infections in low and medium human development index (HDI) countries.

morbidity and mortality burden, the age, geographic and temporal distribution of ETEC, the isolation of ETEC in relation to other diarrhoeagenic pathogens, and the frequency of the different ETEC toxin types. To provide context to its global epidemiology, we also describe ETEC diagnostics and preventive measures. Data gaps and existing research needs are then discussed.

BACKGROUND

Bacteriology

As members of the family Enterobacteriaceae, *Escherichia coli* are mostly Gram-negative, non-spore-forming, motile, lactose-fermenting rods. Although most *E. coli* are non-pathogenic commensal organisms that colonize animal and human intestines, some highly adapted strains can cause human illness.

Enterotoxigenic *E. coli* (ETEC), a cause of watery diarrhoea, belong to a large number of serotypes (defined by the lipopolysaccharide O antigen, flagellar H antigen and capsular K antigen types). They are defined by the ability to produce the heat-labile toxin (LT), heat-stable toxin (ST), or both (LT/ST). More than 20 colonization factors (CFs), found in adhesive fimbriae or bacterial cell surfaces, have also been identified. Immunity is poorly understood, but antibodies to both serotype-specific antigens and LT are thought to confer protective immunity [3]. Although a single individual can suffer repeated ETEC infections, persons living in endemic areas and exposed to multiple strains often develop immunity to a broad range of ETEC strains.

The infectious dose of ETEC is high, and estimated to range from 10^6 to 10^{10} organisms [4], although vulnerable populations such as children and the elderly may be susceptible to infection at lower doses. In order to cause diarrhoea, small intestine colonization, enterotoxin elaboration and action on enterocytes must all occur. The CFs promote small intestine colonization. Secretory watery diarrhoea can be caused by either LT or ST, both of which stimulate chloride secretion and inhibit chloride absorption in small intestine epithelial cells. LT is structurally and functionally similar to cholera toxin; ST is a very small protein that does not appear to elicit an immune response. The role of different CFs in determining severity of illness is poorly understood [5, 6].

The effect of antimicrobial use on the course of illness caused by ETEC is poorly understood, as diagnosis of ETEC is expensive and not readily available to most clinicians. Antimicrobial resistance to drugs such as ampicillin and trimethoprim-sulfamethoxazole is common. If antimicrobial agents are used, fluoroquinolones such as ciprofloxacin or norfloxacin are typically recommended [7, 8], although resistance to these antimicrobials has been documented as well [9], and their use in children is controversial.

Clinical features

The incubation period of ETEC is typically between 10 h and 3 days. Illnesses typically last for 3–5 days; shorter or longer duration illness can also occur [10]. ETEC infection is characterized by watery diarrhoea with either no fever or a low grade fever, but symptoms can also include abdominal cramping and vomiting. Severe, life-threatening dehydration can occur. Extraintestinal complications, such as bacteraemia, are not generally seen with ETEC infections.

Role of environmental and social factors

ETEC is found in both animal and human intestines. Although virulence factors, such as CFs and LT and ST subtypes, and infecting strains are generally species-specific [11, 12], animal strains have been reported to cause illness in humans [13]. Porcine ST toxin (STp) causes disease in humans, and diagnostic methods which differentiate STp from human ST toxin (STh) may help identify differences in the epidemiology of these two strains [14]. Unlike Shigellae or *E. coli* O157:H7, the high infectious dose of ETEC makes direct person-to-person spread rare. Instead, ETEC are primarily transmitted through contaminated food and water. In young infants who may become ill with a lower infectious dose than adults, the introduction of water or weaning foods has been shown to lead to ETEC infections as early as age 3 months [15]. Poor drinking water quality, lack of a sewage system and feeding of supplementary foods were found to be risk factors for ETEC infection in a study of Ecuadorian infants [16]. In Bangladesh, ETEC has also been found to be a major cause of epidemic watery diarrhoea during floods [17]. Countries with the highest incidence of ETEC infection tend to have rapid population growth, periurban areas with poor infrastructure combined with rapid

Table 1. *Terms used in literature search to identify gaps in data on enteric disease burden*

| |
|--|
| Burden of disease |
| Epidemiology |
| Morbidity |
| Mortality |
| Disease outbreaks |
| Incidence |
| Prevalence |
| Seasons |
| Population surveillance |
| Age distribution |
| Longitudinal survey |
| Pathogen-specific terms for Enterotoxigenic <i>E. coli</i> |
| <i>Escherichia coli</i> |
| <i>E. coli</i> infections |
| Heat-stable toxin (<i>E. coli</i>) |
| Enterotoxin heat-labile toxin |

urbanization, sewage-contaminated drinking water and poor sanitary facilities. The epidemiology of ETEC is therefore related to poor socioeconomic conditions.

METHODS

We systematically searched the English-language scientific literature published between 1984 and 2005, using the Medline database, restricting the search to low and medium development countries according to the Human Development Index, United Nations Development Programme (accessed at www.hdr.undp.org). A set of articles containing the key words epidemiol-, morbidity, mortality, disease outbreaks, incidence, prevalence, seasons, population surveillance, age distribution, and longitudinal survey was linked with a set of pathogen-specific terms (Table 1). The resulting cross-linked set was reviewed for publications that contained information addressing specific questions on morbidity, mortality, age distribution, geographic distribution, temporal distribution, pathogen-specific preventive measures, and diagnostics. Population-based studies with culture confirmation of cases were considered primary data sources. When these were lacking, hospital-based studies were considered. Publications were then evaluated for their contribution to an understanding of the global epidemiology of ETEC, and gaps in the data were identified.

Publications were sought with information on the incidence of the infection by region according to the 21 regions of the United Nations Department of Social and Economic Affairs, Population Division (<http://esa.un.org/unpp/>). We examined the correlation between the incidence of ETEC infection and the national *per capita* gross domestic product, adjusted for purchasing power parity in year 2000 dollars, at the time that the studies were conducted (http://unstats.unm.org/unsd/cdb/cdb_series_xrxx.asp?series_code=29922). We searched for publications with information on the age-specific incidence, morbidity, seasonality, mortality, preventive measures and diagnostics. We examined the frequency of ETEC relative to other diarrhoea-causing pathogens including *Salmonella*, *Shigella*, *Vibrio cholerae* O1, *Campylobacter* and *Rotavirus*. In studies in which stools of healthy controls were tested in addition to those with diarrhoea, we report frequency of ETEC isolation only among those with diarrhoea, but discuss the impact of asymptomatic infection on estimates of disease incidence separately.

RESULTS

Morbidity

Incidence

In a 2004 review, the annual number of ETEC cases in the developing world was estimated at 840 million episodes, with another 50 million asymptomatic carriers in children aged <5 years [1]. Incidence of symptomatic infections was estimated at 500 cases/1000 person-years for children aged <5 years, and 100 cases/1000 person-years for older persons. These figures were derived by estimating the total number of diarrhoeal cases and multiplying that by the proportion attributable to ETEC, as determined by the yield of ETEC in stool among persons with diarrhoea found in a variety of studies and age groups.

In this review of the published literature from 1984 to 2005, we found 15 population-based studies of ETEC incidence in low and medium human development index (HDI) countries (Table 2) [18–32]. Fourteen of these studies were conducted in ten medium-HDI countries, representing Asia (8), Africa (2), and Latin America and the Caribbean (4). The fifteenth study was conducted in a low-HDI country, Guinea-Bissau.

Table 2. Population-based studies of ETEC incidence published 1984–2005

| Region | Country | HDI | Study year(s) | Age groups | Size of cohort | Total person-years | Crude incidence* | Incidence calculation† | % of diarrhoea cases with ETEC | Pathogenicity | | | Ref. |
|-----------|---------------|-----|---------------|------------|----------------|--------------------|------------------|------------------------|--------------------------------|--------------------------------------|---------------|-----------------|------|
| | | | | | | | | | | Odds ratio (95% confidence interval) | | | |
| | | | | | | | | | | ST-ETEC | LT-ETEC | ST/LT-ETEC | |
| N Africa | Egypt | Med | 1993–95 | <3 yr | 242 | 216 | 600 | Author | 20 | 2.3 (1.4–3.7) | 1.5 (1.0–2.4) | n.s. | [18] |
| N Africa | Egypt | Med | 1995–98 | <3 yr | 608 | n.r. | 1470 | Author | n.r. | | | | [19] |
| W Africa | Guinea-Bissau | Low | 1997–98 | <2 yr | 200 | 201 | 4460 | JK-calc | n.r. | 1.8 (1.3–2.5) | 0.8 (0.6–1.1) | 1.2 (0.8–1.8) | [20] |
| SE Asia | Myanmar | Med | 1982–83 | <5 yr | 1447 | n.r. | 300–1600 | SKG-calc | 18 | | | | [22] |
| SC Asia | India | Med | 1985–86 | <3 yr | 794 | 768 | 39 | SKG-calc | 14 | | | | [21] |
| E Asia | China | Med | 1986–87 | All | 19 410 | n.r. | 99 | JK-calc‡ | 14 | 1.7 (1.1–2.6) | 1.2 (0.9–1.7) | 11.7 (3.6–46.3) | [25] |
| SE Asia | Thailand | Med | 1988–89 | <5 yr | 482 | n.r. | 64 | JK-calc | 7 | | | | [23] |
| SE Asia | Thailand | Med | 1988–89 | <5 yr | 452 | n.r. | 69 | SKG-calc | 7 | | | | [24] |
| SE Asia | Indonesia | Med | 1993–94 | <5 yr | 297 | n.r. | 616 | JK-calc | 34 | | | | [26] |
| SE Asia | Indonesia | Med | 1994 | <5 yr | 408 | n.r. | 300 | Author | 20 | | | | [27] |
| SE Asia | Vietnam | Med | 1998–99 | <5 yr | 1655 | n.r. | 80 | JK-calc | 7 | | | | [28] |
| S America | Brazil | Med | 1978–79 | All | 189 | 304 | 141 | JK-calc | 27 | | | | [29] |
| S America | Peru | Med | 1982–84 | <1 yr | 153 | n.r. | 730 | JK-calc‡ | 7 | 1.7 (1.3–2.2) | 1.6 (1.1–2.2) | 4.0 (2.9–5.6) | [32] |
| S America | Brazil | Med | 1984–86 | <5 yr | 175 | n.r. | 1370 | JK-calc | 14 | | | | [30] |
| C America | Nicaragua | Med | 1991–94 | <2 yr | 235 | 470 | 660 | JK-calc‡ | 38 | 1.7 (1.0–3.0) | 0.8 (0.6–1.3) | 1.0 (0.4–2.2) | [31] |

ETEC, Enterotoxigenic *E. coli*; HDI, human development index; ST, heat-stable toxin; LT, heat-labile toxin; n.r., not reported; n.s., data not sufficient.

* Crude incidence reported as number of cases/1000 persons per year.

† Author: incidence reported by author of paper; JK-calc or SKG-calc: incidence calculated by the investigators.

‡ Odds ratios for toxin types calculated using Epi-Info v.3.3.2, based on numbers of ill/well individuals with positive/negative toxin tests.

Table 3. Age-specific incidence of ETEC infections in population-based studies, published 1984–2005

| Area | Asia | Africa | Africa |
|-----------------|---------|----------|----------|
| Region | SE Asia | N Africa | N Africa |
| Country | Vietnam | Egypt | Egypt |
| HDI | Medium | Medium | Medium |
| Study years | 1998–99 | 1993–95 | 1995–98 |
| Age range | < 5 yr | < 3 yr | < 3 yr |
| ETEC incidence* | 80 | 600 | 1470 |
| 0–5 months | 250 | 1000 | 1670 |
| 6–11 months | | | 2260 |
| 12–17 months | 140 | 600 | 1990 |
| 18–23 months | | | 1350 |
| 24–35 months | 20 | 100 | 760 |
| 36–48 months | 50 | | |
| 49–60 months | 20 | | |
| Reference | [28] | [18] | [19] |

ETEC, Enterotoxigenic *E. coli*; HDI, human development index.

* Incidence reported as number of episodes/1000 person-years.

The incidence data presented in Table 2 were reported by the authors of three studies and calculated by the investigators based on data provided for the other 12 studies. Crude incidence estimates are given, without correction for age categories, sensitivity of diagnostic methods for ETEC, asymptomatic or LT-ETEC infection, or for the proportion of diarrhoeal episodes for which stool specimens were not collected. The study methodologies varied widely and incidence results are not comparable. In these 15 studies, longitudinal surveillance visits were conducted daily (3), three times a week (2), twice a week (5), weekly (4) or monthly (1). Eleven different definitions of diarrhoea were used and seven different algorithms were used for identification of ST and LT enterotoxins.

Among the two studies reporting on surveillance among all age groups, from China and Brazil, ETEC incidence was similar, 99 and 141 cases/1000 person-years. The other 13 studies included different subsets of children aged < 5 years, and showed a wide range of incidence (39–4460 cases/1000 person-years), with no clear pattern by region, HDI level or population setting.

We did not find any published population-based studies of ETEC incidence from any country in sub-Saharan Africa or West Asia.




Fig. Age-specific incidence of ETEC infections in population-based studies, published 1984–2005. * In order to compare results in one figure, incidence is expressed as the incidence for the indicated age group, divided by the incidence for infants aged 0–12 months.

Age distribution

Neither of the two population-based studies of ETEC disease incidence which included all age groups reported age-specific incidence [25, 29]. However, three population-based studies of ETEC disease incidence among children only reported age-specific incidence (Table 3). All three studies showed the same pattern of peak incidence in the first year of life, with subsequent declines in incidence (Fig.). Rao *et al.* stratified infants by age and showed that the peak incidence is after 6 months and may last until age 18 months [19]. Children aged > 6 months may be at increased risk due to reduced levels of maternal antibodies and increased consumption of contaminated water or foods.

Temporal distribution

Seventeen studies reported seasonality of ETEC infections. Of these, three reported no seasonal variation [32–34]. Another ten reported a higher incidence in the hot season [12, 22, 35–42]. The other four studies reported that ST-ETEC had a higher incidence in the hot season, but LT-ETEC showed no seasonal variation [18, 19, 43, 44]. No consistent patterns were seen when comparing wet and dry seasons.

Geographic distribution

The geographic distribution of ETEC is illustrated based on data from population-based studies presented in Table 2. Incidence ranges from 39 to 4460 cases/1000 person-years. Results from these specific study sites cannot be generalized to an entire country or geographic region. These rates are considerably higher than most other bacterial enteric infection rates, such as *Shigella* [45] and *Salmonella* Typhi [46]. No data were available for Eastern, Middle and Southern Africa and Western Asia. The highest ETEC incidence was reported from North and West Africa.

Frequency of ETEC relative to other diarrhoeagenic pathogens

We found 70 publications that described the frequency of ETEC in diarrhoea stools or the relative frequency of ETEC compared to other enteric pathogens. Table 4 summarizes these publications and includes the age of the population surveyed, the total number of stool samples or rectal swabs obtained, and where reported, the total proportion of samples yielding at least one pathogen. Studies varied widely with respect to the overall spectrum of pathogens tested. When available, the proportion of isolates yielding *Salmonella*, *Vibrio cholerae*, ETEC, *Campylobacter*, *Rotavirus*, and *Shigella* are reported. ETEC is assigned a rank among the pathogens based on data presented in Table 4 as well as data regarding other pathogens, such as enteropathogenic *E. coli*, which may have been presented in the studies under consideration.

The 70 studies represent Asia (42), Africa (16), Latin America and the Caribbean (10) and Oceania (2). One study was conducted in four different low- or medium-HDI countries [47] and is considered here as four distinct studies. Of 52 studies with relative frequency of pathogens other than ETEC, ETEC was the most frequently isolated pathogen in 21 (40%) studies and the second most frequently isolated in another 14 (27%) studies. ETEC was the first or second most frequently isolated pathogen in nine (75%) of the 12 studies conducted in Africa, 22 (65%) of 34 studies in Asia and three (50%) of six studies in Latin America and the Caribbean. Notably, only 37 (73%) of the 51 studies tested for and reported results of *Campylobacter* isolation, and only 32 (63%) tested for and reported results of *Rotavirus* infection. Most studies did not include identification of parasitic aetiologies of diarrhoea.

Among the 19 studies conducted with all age groups, a median of 14% of diarrhoeal specimens were positive for ETEC (range 2–36%). Among the 51 studies conducted among children only, a median of 13% of diarrhoeal episodes were positive for ETEC (interquartile range 3–39%).

Frequency of ETEC toxin phenotypic subgroups

Knowledge of the distribution of ETEC toxin phenotypic subgroups in a population may be useful to assess endemic disease incidence, as LT-ETEC is thought to be less likely to cause disease than ST-ETEC or LT/ST-ETEC [48]. Pathogenicity of LT-ETEC may be in part determined by the presence of specific CFs. The literature review yielded a total of 50 studies assessing the relative frequency of the three ETEC enterotoxin subgroups (Table 5). ST-ETEC was the most commonly detected subgroup in 27 of these, LT-ETEC in another 19, and ST/LT-ETEC in the remaining four. There was wide variability in the frequency of toxin phenotypic subgroups among ETEC isolates. The range (median) of frequency was 1–98% (30%) for LT-ETEC, 0–92% (45%) for ST-ETEC, and 0–52% (14%) for LT/ST-ETEC. This wide variation was seen in Africa, Asia and Latin America. No relationship between relative frequency of toxin phenotypic subgroups and study age group, year of study or study setting was noted.

Five of the 15 population-based studies of ETEC incidence obtained sufficient data to determine the pathogenicity of different toxin types (Table 2) [18, 20, 25, 31, 32]. In all five of these studies, ill patients were more likely to have ST-ETEC isolated from their stools than well patients. However, in only two of five studies LT-ETEC was more likely to be isolated from ill patients, and in two or four studies ST/LT-ETEC was more likely to be isolated from ill patients. These results are consistent with facility-based case-control studies which suggest that LT-ETEC, or certain strains of LT-ETEC may be infrequently pathogenic [48].

Three studies described the relative frequency of toxin phenotypic subgroups during three different ETEC outbreaks in India [9, 49, 50]. All ETEC isolates from each outbreak were positive for LT and negative for ST, suggesting that LT-ETEC does cause clinical illness. Outbreaks of watery diarrhoea due to ETEC may often go unrecognized because of the unavailability of tests for LT and ST outside research settings.

Table 4a. *Relative frequency of endemic ETEC isolation, community- and facility-based studies conducted among all age groups, published 1984–2005*

| Area | Region | Country | HDI | Study type | Study years | No. of samples tested | % pos. for any pathogen | % ETEC | % Sa | % VC | % RV | % Sh | % Ca | ETEC rank | Ref. |
|---------------|-----------|-------------|-----|-----------------|-------------|-----------------------|-------------------------|--------|------|------|------|------|------|-----------|------|
| Africa | E Africa | Djibouti | Low | Clinic | 1989 | 209 | n.r. | 11 | 3 | n.t. | n.t. | 8 | 3 | 1 | [80] |
| Africa | W Africa | Nigeria | Low | Hospital | 1995–96 | 852 | 21 | 2 | 17 | n.t. | n.t. | 21 | n.t. | 4 | [85] |
| Asia | SE Asia | Thailand | Med | Cohort | 1982–83 | 177 | n.r. | 10 | n.t. | n.t. | n.t. | 4 | n.r. | 1 | [38] |
| Asia | SC Asia | India | Med | Hospital | 1982–83 | 240 | n.r. | 12 | 0 | 33 | 8·8 | 5 | 7 | 2 | [86] |
| Asia | SE Asia | Thailand | Med | Clinic | 1982–83 | 299 | 30 | 17 | n.t. | 2 | n.t. | 9 | n.t. | 1 | [87] |
| Asia | SE Asia | Philippines | Med | Hospital | 1983 | 1021 | n.r. | 7·8 | 12 | 4·1 | 27 | 10 | 4 | 3 | [33] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1983–84 | 2635 | 69 | 14 | 1 | 39 | n.t. | 11 | 11 | 2 | [39] |
| Asia | SC Asia | Iran | Med | Clinic | 1984 | 273 | n.r. | 22 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [88] |
| Asia | E Asia | China | Med | Cohort | 1986–87 | 2265 | 39 | 14 | 0 | 0·8 | n.t. | 11 | 3 | 1 | [25] |
| Asia | SE Asia | Thailand | Med | Hospital | 1991 | 363 | n.r. | 7 | 8 | n.t. | n.t. | 16 | 5 | 3 | [89] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1995 | 113 | 87 | 36 | 1 | 24 | 10 | 8 | 5 | 1 | [90] |
| Asia | SE Asia | Laos | Med | Hospital | 1996–97 | 880 | 43 | 20 | 1 | 0 | n.t. | 17 | 4 | 1 | [43] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1996–98 | 4662 | n.r. | 14 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [37] |
| Asia | SC Asia | Indonesia | Med | Hospital | 2000–01 | 489 | n.r. | 15 | 3 | 0·2 | n.t. | 3 | 0 | 1 | [44] |
| Asia | SE Asia | Indonesia | Med | Hospital | n.r. | 1169 | n.r. | 19 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [82] |
| Latin America | S America | Brazil | Med | Cohort | 1978–79 | 110 | 62 | 27 | 5 | n.t. | n.t. | 15 | n.t. | 1 | [29] |
| Latin America | S America | Peru | Med | Hospital/clinic | 1992–93 | 143 | 52 | 22 | 4 | 31 | n.t. | 3 | 3 | 2 | [91] |

ETEC, Enterotoxigenic *E. coli*; HDI, human development index; Sa, *Salmonella* (includes typhoidal and non-typhoidal serotypes); VC, *Vibrio cholerae*; RV, Rotavirus numbers; Sh, *Shigella*; Ca, *Campylobacter*; n.r., not reported; n.t., not tested; n.c., not calculable.

Table 4b. *Relative endemic ETEC isolation frequency, community- and facility-based studies conducted among restricted age groups, published 1984–2005*

| Area | Region | Country | HDI | Study type | Study years | Age range | No. samples tested | % pos. for any pathogen | % ETEC | % Sa | % VC | % RV | % Sh | % Ca | ETEC rank | Ref. |
|---------------|-----------|--------------|-----|-----------------|-------------|-----------|--------------------|-------------------------|--------|------|------|------|------|------|-----------|-------|
| Asia | SC Asia | India | Med | Hospital | 1986–88 | <6 mo. | 218 | n.r. | 12 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [92] |
| Asia | E Asia | China | Med | Clinic | 1989 | <1 yr | 174 | 34 | 4 | | | 13 | 1 | 10 | 2 | [74] |
| Latin America | S America | Peru | Med | Cohort | 1982–84 | <1 yr | 952 | 41 | 7 | 1 | 0 | 3 | 2 | 10 | 2 | [32] |
| Latin America | S America | Brazil | Med | Hospital | 1985–86 | <1 yr | 500 | 55 | 7 | 8 | | 14 | 5 | 3 | 4 | [36] |
| Africa | W Africa | Gambia | Low | Cohort | 1981–84 | <2 yr | 516 | 28 | 10 | 1 | 0 | 6 | 2 | 4 | 1 | [76] |
| Africa | S Africa | South Africa | Med | Hospital | 1982–83 | <2 yr | 478 | 46 | 4 | 7 | 2 | 26 | 4 | 11 | 4 | [71] |
| Latin America | S America | Brazil | Med | Clinic | 1989 | <2 yr | 126 | 83 | 10 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [79] |
| Latin America | C America | Nicaragua | Med | Cohort | 1991–94 | <2 yr | 808 | n.r. | 38 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [31] |
| Africa | N Africa | Egypt | Med | Cohort | 1993–95 | <3 yr | 628 | n.r. | 20 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [18] |
| Africa | N Africa | Egypt | Med | Cohort | 1995–98 | <3 yr | 2201 | n.r. | 28 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [60] |
| Africa | S Africa | South Africa | Med | Hospital | n.r. | <3 yr | 78 | 77 | 39 | 4 | 0 | 13 | 1 | 15 | 1 | [93] |
| Latin America | S America | Brazil | Med | Hospital | 1994–95 | <3 yr | 199 | n.r. | 4 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [75] |
| Asia | E Asia | China | Med | Clinic | 1982–85 | <3 yr | 594 | n.r. | 6 | 5 | 0 | 13 | 18 | 17 | 4 | [47] |
| Asia | SE Asia | Myanmar | Med | Clinic | 1982–85 | <3 yr | 813 | n.r. | 26 | 1 | 1 | 22 | 3 | 2 | 1 | [47] |
| Asia | S Asia | India | Med | Clinic | 1982–85 | <3 yr | 915 | n.r. | 14 | 4 | 2 | 18 | 20 | 15 | 4 | [47] |
| Asia | S Asia | Pakistan | Low | Clinic | 1982–85 | <3 yr | 758 | n.r. | 17 | 3 | 2 | 14 | 6 | 10 | 1 | [47] |
| Asia | S Asia | Pakistan | Low | Hospital | 1983–84 | <3 yr | 250 | 76 | 14 | 3·2 | n.t. | 10 | 4 | n.t. | 2 | [94] |
| Asia | SC Asia | India | Med | Cohort | 1985–86 | <3 yr | 222 | 54 | 14 | 3 | 0 | 2 | 2 | 6 | 1 | [21] |
| Asia | SC Asia | India | Med | Cohort | 1985–86 | <3 yr | 179 | 44 | 15 | 3 | 0 | 2 | 2 | 6 | 1 | [95] |
| Asia | W Asia | Iraq | NR | Hospital | 1988–89 | <3 yr | 304 | n.r. | 13 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [96] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1988–89 | <3 yr | 969 | 64 | 16 | <1 | 5 | 29 | 3 | 27 | 3 | [97] |
| Africa | N Africa | Egypt | Med | Hospital/clinic | 1986 | <5 yr | 151 | n.r. | 17 | 7 | | 18 | 5 | 7 | 2 | [98] |
| Africa | W Africa | Nigeria | Low | Clinic | 1989–90 | <5 yr | 215 | 75 | 14 | 3 | | 22 | 5 | n.t. | 2 | [78] |
| Africa | E Africa | Tanzania | Low | Clinic | 1990 | <5 yr | 394 | n.r. | 20 | n.t. | n.t. | n.t. | n.t. | 18 | n.c. | [34] |
| Africa | E Africa | Tanzania | Low | Hospital | 1997 | <5 yr | 103 | 63 | 16 | 0 | n.t. | 4 | 13 | n.t. | 1 | [81] |
| Africa | W Africa | Nigeria | Low | Clinic | n.r. | <5 yr | 187 | n.r. | 3 | 1 | n.t. | n.t. | 1 | n.t. | 1 | [73] |
| Africa | E Africa | Kenya | Low | Hospital | n.r. | <5 yr | 300 | n.r. | 6 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [77] |
| Asia | SE Asia | Thailand | Med | Clinic | 1982 | <5 yr | 221 | n.r. | 14 | 1 | 2 | n.t. | 9 | n.t. | 1 | [99] |
| Asia | SE Asia | Myanmar | Med | Cohort | 1982–83 | <5 yr | 501 | n.r. | 18 | 1 | n.t. | 5 | 2 | 2 | 1 | [22] |
| Asia | SE Asia | Thailand | Med | Clinic | 1985–86 | <5 yr | 1230 | 63 | 9 | 12 | 1 | 20 | 13 | 13 | 5 | [70] |
| Asia | SE Asia | Thailand | Med | Clinic | 1985–86 | <5 yr | 1230 | n.r. | 13 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [100] |
| Asia | SE Asia | Thailand | Med | Cohort | 1988–89 | <5 yr | 345 | 54 | 7 | 13 | 0 | 12 | 6 | 14 | 4 | [23] |
| Asia | SE Asia | Thailand | Med | Cohort | 1988–89 | <5 yr | 345 | 56 | 7 | 9 | 0 | 9 | 5 | 9 | 4 | [24] |
| Asia | SE Asia | Indonesia | Med | Hospital | 1988–89 | <5 yr | 194 | 28 | 8 | 19 | 3 | | 2 | 6 | 2 | [101] |
| Asia | W Asia | Jordan | Med | Hospital | 1993–94 | <5 yr | 256 | 66 | 6 | 5 | 0 | 33 | 5 | 2 | 4 | [54] |
| Asia | SE Asia | Vietnam | Med | Cohort | 1998–99 | <5 yr | 2160 | 22 | 7 | 1 | n.t. | n.t. | 6 | 7 | 2 | [28] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1991–92 | <5 yr | 451 | n.r. | 12 | 1 | 10 | 17 | 10 | n.t. | 3 | [41] |

| | | | | | | | | | | | | | | | | |
|---------------|---------------|--------------|------|-----------------|---------|-----------|------|------|----|------|------|------|------|------|------|-------|
| Asia | SC Asia | Bangladesh | Med | Hospital | 1993-94 | <5 yr | 814 | 75 | 17 | 2 | 5 | 20 | 9 | 17 | 3 | [40] |
| Asia | SE Asia | Indonesia | Med | Cohort | 1993-94 | <5 yr | 179 | n.r. | 34 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [26] |
| Asia | SE Asia | Indonesia | Med | Cohort | 1994 | <5 yr | 241 | n.r. | 14 | 2 | 7 | n.t. | 1 | 2 | 1 | [27] |
| Latin America | S America | Brazil | Med | Cohort | 1984-86 | <5 yr | 90 | 53 | 14 | n.t. | n.t. | 21 | 2 | 3 | 3 | [30] |
| Latin America | S America | Bolivia | Med | Hospital | 1991-92 | <7 yr | 195 | n.r. | 3 | 1 | 8 | n.t. | 3 | n.t. | 6 | [102] |
| Latin America | S America | Brazil | Med | Clinic | 1993 | <5 yr | 76 | n.r. | 16 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [103] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1982-83 | <8 yr | 104 | 59 | 9 | n.c. | 11 | 17 | 5 | 20 | 5 | [72] |
| Oceania | Melanesia | N. Caledonia | n.r. | Hospital | 1990 | <10 yr | 448 | n.r. | 5 | n.c. | n.c. | n.c. | n.c. | n.c. | n.c. | [104] |
| Oceania | Melanesia | Vanuatu | Med | Hospital/clinic | 1984 | <10 yr | 109 | n.t. | 27 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [84] |
| Asia | SE Asia | Thailand | Med | Clinic | 1996-00 | <12 yr | 2100 | n.r. | 3 | n.t. | n.t. | n.t. | n.t. | n.t. | n.c. | [105] |
| Africa | Middle Africa | CAR | Low | Hospital/clinic | 1981-82 | <15 yr | 1197 | 64 | 3 | 5 | 18 | 3 | 11 | 5 | 5 | [106] |
| Africa | E Africa | Somalia | n.r. | Hospital | 1983-84 | <15 yr | 1667 | 61 | 11 | 4 | 6 | 25 | 9 | 8 | 2 | [35] |
| Asia | SC Asia | Iran | Med | Hospital | 1986-87 | Children* | 715 | n.r. | 17 | 9 | n.t. | n.t. | 6 | n.t. | 2 | [69] |
| Asia | SC Asia | Iran | Med | Clinic | 1986-87 | Children* | 443 | n.r. | 17 | 4 | n.t. | n.t. | 4 | n.t. | 2 | [69] |
| Asia | E Asia | China | Med | Hospital/clinic | 1989 | Children* | 221 | 56.5 | 20 | 12 | 7 | 3 | 3 | 2 | 1 | [83] |

ETE, Enterotoxigenic *E. coli*; HDI, human development index; Sa, *Salmonella* (includes typhoidal and non-typhoidal serotypes); VC, *Vibrio cholerae*; RV, Rotavirus; Sh, *Shigella*; Ca, Campylobacter; CAR, Central African Republic; n.r., not reported; n.t., not tested; n.c., not calculable.
 * Children: the corresponding study did not describe the age range of children included in the study.

Complications

Extraintestinal complications do not generally occur with ETEC infections. The most concerning acute complication is severe dehydration due to profuse watery diarrhoea and vomiting. In a hospital-based study in Bangladesh from 1996 to 2002, 36% of 478 adults and 3% of 1107 children admitted with ETEC infection had severe dehydration [48]. This is consistent with reports that adults, at least in the Indian subcontinent, frequently present with a severe dehydrating cholera-like illness, although this also could be due to longer delays in reaching a treatment facility [37]. In India, one outbreak of severe watery diarrhoea thought to be due to cholera was found to be due to ETEC [49] and another was found to be due to both cholera and ETEC [9].

ETEC infections may also cause malnutrition and poor weight gain. In one study in rural Bangladesh, ETEC infections were shown to decrease 60-day weight gain in children [51]. In Brazil, childhood diarrhoea was shown to be associated with long-term impaired physical fitness and cognitive function [52], although this has not been studied specifically with ETEC infections.

Mortality

Annual diarrhoeal deaths among children aged <5 years are estimated at 2.5 million based on studies conducted between 1992 and 2000 [53]. If ETEC is responsible for 13% of these deaths, the median proportion of ETEC among diarrhoea cases in this review, 325 000 children (interquartile range 175 000–425 000) aged <5 years would be estimated to die each year from ETEC.

Of the 15 population-based studies of ETEC, only two discuss mortality. In Vietnam, 2160 cases of diarrhoea were identified over one year in 1655 children aged <5 years; of 25 ETEC cases, there were no deaths [28]. In Nicaragua, 885 cases of diarrhoea were reported in the first two years of life among 235 children; of 310 ETEC cases detected among 808 specimens, there were no deaths [31]. Of the hospital-based studies of endemic disease referenced in this report, one discusses mortality; among 265 children admitted with acute diarrhoea, none died [54]. In three epidemics attributed to ETEC in India [9, 49, 50], no patient deaths were reported. If patients with severe ETEC infections reach a treatment facility, the mortality rate should be extremely low. However, most infections may go untreated, and the

Table 5. *Relative frequency of ETEC enterotoxin subgroups in endemic disease, published 1984–2005*

| Area | Region | Country | HDI | Study type | Study years | Age range | No. of diarrhoea samples tested | % of diarrhoea specimens with ETEC | % LT only | % ST only | % LT/ST | Ref. |
|--------|---------------|--------------|-----|-----------------|-------------|-----------|---------------------------------|------------------------------------|-----------|-----------|---------|-------|
| Africa | Middle Africa | CAR | Low | Hospital/clinic | 1981–82 | < 15 yr | 1197 | 3 | 44 | 29 | 26 | [106] |
| Africa | N Africa | Egypt | Med | Cohort | 1981–83 | All | 3513 | 24 | 61 | 36 | 4 | [107] |
| Africa | W Africa | Gambia | Low | Cohort | 1981–84 | < 2 yr | 516 | 10 | 53 | 39 | 6 | [76] |
| Africa | N Africa | Egypt | Med | Hospital/clinic | 1986 | < 5 yr | 151 | 17 | 30 | 61 | 9 | [98] |
| Africa | E Africa | Djibouti | Low | Clinic | 1989 | All | 209 | 11 | 44 | 44 | 13 | [80] |
| Africa | W Africa | Nigeria | Low | Clinic | 1989–90 | < 5 yr | 215 | 14 | 19 | 74 | 7 | [78] |
| Africa | N Africa | Egypt | Med | Cohort | 1993–95 | < 3 yr | 628 | 20 | 34 | 53 | 13 | [18] |
| Africa | W Africa | Nigeria | Low | Hospital | 1995–96 | All | 852 | 2 | 24 | 35 | 41 | [85] |
| Africa | N Africa | Egypt | Med | Cohort | 1995–98 | < 3 yr | 2201 | 28 | 24 | 61 | 7 | [60] |
| Africa | E Africa | Tanzania | Low | Hospital | 1997 | < 5 yr | 103 | 16 | 31 | 56 | 13 | [81] |
| Africa | W Africa | Nigeria | Low | Clinic | n.r. | < 5 yr | 187 | 3 | 17 | 83 | 0 | [73] |
| Africa | S Africa | South Africa | Med | Hospital | n.r. | < 3 yr | 78 | 39 | 77 | 13 | 10 | [93] |
| Asia | SC Asia | India | Med | Hospital | 1982–83 | All | 240 | 12 | 48 | 21 | 31 | [86] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1982–83 | < 8 yr | 104 | 9 | 22 | 56 | 22 | [72] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1983–84 | All | 2635 | 14 | 29 | 50 | 21 | [39] |
| Asia | S Asia | Pakistan | Low | Hospital | 1983–84 | < 3 yr | 250 | 14 | 40 | 49 | 11 | [42] |
| Asia | SC Asia | Iran | Med | Clinic | 1984 | All | 273 | 22 | 17 | 60 | 23 | [88] |
| Asia | SE Asia | Thailand | Med | Clinic | 1985–86 | < 5 yr | 1230 | 9 | 44 | 33 | 22 | [70] |
| Asia | SE Asia | Thailand | Med | Clinic | 1985–86 | < 5 yr | 1230 | 13 | 47 | 30 | 23 | [100] |
| Asia | SC Asia | India | Med | Cohort | 1985–86 | < 3 yr | 222 | 15 | 48 | 30 | 19 | [21] |
| Asia | SC Asia | India | Med | Cohort | 1985–86 | < 3 yr | 222 | 14 | 57 | 27 | 17 | [21] |
| Asia | SC Asia | Iran | Med | Clinic | 1986–87 | All | 443 | 17 | 1 | 92 | 7 | [69] |
| Asia | SC Asia | Iran | Med | Hospital | 1986–87 | Children | 715 | 17 | 12 | 77 | 11 | [69] |
| Asia | E Asia | China | Med | Cohort | 1986–87 | All | 2265 | 14 | 43 | 32 | 25 | [25] |
| Asia | SC Asia | India | Med | Hospital | 1986–88 | < 6 mo. | 218 | 12 | 58 | 31 | 12 | [92] |
| Asia | W Asia | Iraq | Med | Hospital | 1988–89 | < 3 yr | 304 | 13 | 69 | 21 | 10 | [96] |
| Asia | SE Asia | Indonesia | Med | Hospital | 1988–89 | < 5 yr | 194 | 8.2 | 69 | 31 | 0 | [101] |
| Asia | E Asia | China | Med | Clinic | 1989 | < 1 yr | 174 | 4 | 71 | 0 | 29 | [74] |
| Asia | E Asia | China | Med | Hospital/clinic | 1989 | Children | 221 | 20 | 98 | 3 | 0 | [83] |
| Asia | SE Asia | Thailand | Med | Hospital | 1990 | All | 363 | 7 | 18 | 56 | 26 | [99] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1991–92 | < 5 yr | 451 | 12 | 15 | 57 | 24 | [41] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1993–94 | < 5 yr | 814 | 17 | 27 | 50 | 23 | [40] |
| Asia | W Asia | Jordan | Med | Hospital | 1993–94 | < 5 yr | 256 | 6 | 60 | 27 | 13 | [54] |
| Asia | SE Asia | Indonesia | Med | Cohort | 1994 | < 5 yr | 241 | 20 | 34 | 52 | 24 | [27] |
| Asia | SE Asia | Laos | Med | Hospital | 1996–97 | All | 880 | 20 | 13 | 84 | 3 | [43] |
| Asia | SC Asia | Bangladesh | Med | Hospital | 1996–98 | All | 4662 | 14 | 25 | 49 | 25 | [37] |

| | | | | | | | | | | | | |
|---------------|-----------|---------------|------|-----------------|-----------|--------|------|----|----|----|----|-------|
| Asia | SE Asia | Thailand | Med | Clinic | 1996-2000 | <12 yr | 2100 | 3 | 39 | 54 | 8 | [105] |
| Asia | SC Asia | Indonesia | Med | Hospital | 2000-01 | All | 489 | 15 | 29 | 70 | 1 | [44] |
| Asia | SE Asia | Indonesia | Med | Hospital | n.r. | All | 1169 | 19 | 23 | 71 | 6 | [82] |
| Latin America | S America | Brazil | Med | Cohort | 1978-79 | All | 110 | 27 | 20 | 60 | 20 | [29] |
| Latin America | S America | Peru | Med | Cohort | 1982-84 | <1 yr | 952 | 7 | 50 | 36 | 14 | [32] |
| Latin America | S America | Brazil | Med | Hospital | 1985-86 | <1 yr | 500 | 7 | 42 | 45 | 12 | [36] |
| Latin America | S America | Brazil | Med | Cohort | 1986 | <5 yr | 90 | 14 | 43 | 14 | 43 | [30] |
| Latin America | S America | Brazil | Med | Clinic | 1989 | <2 yr | 126 | 10 | 50 | 8 | 42 | [79] |
| Latin America | C America | Nicaragua | Med | Cohort | 1991-94 | <2 yr | 808 | 38 | 24 | 34 | 42 | [31] |
| Latin America | S America | Peru | Med | Hospital/clinic | 1992-93 | All | 143 | 22 | 16 | 68 | 16 | [91] |
| Latin America | S America | Brazil | Med | Clinic | 1993 | <5 yr | 76 | 16 | 19 | 31 | 50 | [103] |
| Oceania | Melanesia | Vanuatu | Med | Hospital/clinic | 1984 | <10 yr | 109 | 27 | 24 | 24 | 52 | [84] |
| Oceania | Melanesia | New Caledonia | n.r. | Hospital | 1990 | <10 yr | 448 | 5 | 21 | 71 | 8 | [104] |

ETEC, Enterotoxigenic *E. coli*; HDI, human development index; LT, heat-labile toxin; ST, heat-stable toxin; CAR, Central African Republic; n.r., not reported.

case-fatality rate (CFR) for untreated infections is unknown.

Pathogen-specific preventive measures

Vaccine strategies

Efforts to develop an effective and useful ETEC vaccine are ongoing. Many different antigens have been considered in vaccine development including O antigens, H antigens, CFs and toxins. At least 78 O antigens and 34 H antigens have been identified in ETEC isolates, with no predominant serotype or group of serotypes [55, 56]. O and H antigens are known to confer protective immunity [57], and infection with multiple serotypes is believed to confer immunity to the predominant ETEC strains present in a community. However, because of the large number of O and H antigens, these have not been considered practical targets for vaccine development unless common epitopes can be identified [3, 55]. The ST toxin is not immunogenic because of its small size (only 19 amino acids), and efforts to design a ST-conjugate antigen that confers protective immunity against ST-ETEC have not yet been successful [56].

A 1988 study showed 67% short-term, 3-month protection against illness from LT-ETEC by a B subunit whole-cell oral cholera vaccine [58], providing hope for the development of an ETEC vaccine. Current experimental ETEC vaccines currently target the LT toxin as well as some of the CFs [3]. However, this strategy is limited because of the small proportion of ETEC illnesses attributable to LT-ETEC, the large number of CFs, the high proportion of ETEC isolates without identifiable CFs, the finding that CFs may not effectively confer protective immunity [59], and the lack of effectiveness of a candidate vaccine in a recent trial [60]. The success of future vaccine development efforts will depend on the ability to find or design the best vaccine antigens for protective immunity, and to find effective methods of vaccine delivery for optimal antigen presentation [61].

Non-vaccine strategies

Both young age and pre-existing malnutrition have been found to be associated with more severe ETEC infections [62, 63]. The effect of micronutrient deficiencies such as vitamin A and zinc on risk for severe ETEC infection is unknown. Exclusive breastfeeding

of infants has been shown to protect against severe ETEC infections, but this effect was not seen with partial breastfeeding or with children aged >1 year [64].

Non-vaccine measures for the prevention of ETEC include exclusive breastfeeding of infants [64, 65], sanitary preparation of weaning foods for infants [65], promotion of handwashing and hygiene, control of houseflies [66], sanitary disposal of human faeces, provision of safe drinking water at the point of consumption through improved water supplies, household water disinfection and safe water storage [67], sanitary food preparation and storage [10], and the provision of safe drinking water during flood disasters [68].

Diagnostics

Testing for both LT and ST in *E. coli* isolates is the established method for the identification of ETEC. Traditionally, enterotoxins have been detected with immunoassays or bioassays. Because of the large number of serotypes associated with ETEC, serotyping is not as useful for diagnosis. Because it is faster, detection of the LT or ST gene through the use of DNA probes or PCR amplification has become common. In incidence studies, the differences in sensitivity of different diagnostic methods may partially explain the wide variety in incidence estimates, relative frequency of ETEC in diarrhoeal stools and relative frequency of ETEC toxin types. However, as all ETEC diagnostic methods are widely unavailable in most clinical laboratories in both the developing and developed world, ETEC is likely under-recognized outside of research settings.

DATA GAPS AND DISCUSSION

This review describes the available data and highlights the major gaps in data (below) regarding the global epidemiology of ETEC infections. A successful research agenda based on these data gaps could be expected to help appropriately direct resources for prevention and control activities in order to more efficiently reduce the burden of illness due to ETEC. This research can be performed for multiple diarrhoeagenic pathogens simultaneously in order to both reduce costs and better understand the relative contribution of different pathogens to age-specific morbidity and mortality.

The major data needs for incidence, including age, temporal and geographic distribution are:

- population-based surveillance for ETEC incidence in low-HDI countries, especially in sub-Saharan Africa, including testing in both ill and well participants;
- population-based surveillance, with incidence reported for total population as well as by toxin type and age group, including young (<6 months) and older (6–12 months) infants, including testing in both ill and well participants;
- population based-surveillance among multiple sites in a country or region to determine the generalizability of data from a specific study site;
- temporal distribution of ETEC over multi-year periods, with reporting using consistent descriptors and contextual environmental information such as rainfall and flooding;
- comprehensive stool analyses, using state-of-the-art diagnostic methods, including isolation of *Shigella*, *Campylobacter*, enteropathogenic *E. coli* (EPEC), *Rotavirus*, and parasitic infections, in studies of relative frequency of diarrhoeagenic pathogens, including testing in both ill and well participants;
- further characterization of the pathogenicity of different ETEC toxin types and strains in both primary and repeat infections, as well as the impact of infection with multiple pathogens on disease incidence and severity.

Diarrhoea incidence is extremely variable and estimates of pathogen-specific incidence may not be generalizable to populations outside of a specific study site, or to the same study population at a different season, or even the same season in a different year. Estimates of ETEC disease incidence are further complicated by a number of other pathogen-specific factors. The frequency of asymptomatic infection ranges from 0% to 22% [22, 25, 30–36, 40–42, 44, 47, 69–84], and as many as 40% of ill persons with ETEC have other pathogens in their stools, making it difficult to know which pathogen caused the illness [40]. Furthermore, multiple case-control studies have shown that cases are no more likely to have LT-ETEC than controls; therefore, LT-ETEC is thought to less commonly cause ETEC disease or severe ETEC disease than ST-ETEC or LT/ST-ETEC [48, 60]. ST-ETEC may be more pathogenic because the heat-stable toxin does not cause an immune response, and the pathogenicity of LT-ETEC

may be largely limited to first infections of a given strain.

Because of these pathogen-specific factors, ETEC disease incidence estimates from population-based studies may be artificially elevated as they generally do not control for asymptomatic infection or infection with multiple pathogens. At the same time, ETEC is clinically under-recognized as a pathogen, as most clinical laboratories in both resource-poor and resource-rich countries lack the capacity to test for it.

Perhaps the most striking data gap is the absence of population-based data from low-HDI countries, especially in sub-Saharan Africa. These countries may have a high incidence of ETEC infection, and understanding this epidemiology will assist in projecting the impact of pathogen-specific and non-specific preventive measures.

A better understanding of age-specific incidence is also needed; only one study describes the incidence in both young and older infants. Further data may help define age groups at highest risk of infection and complications, as well as the role of breastfeeding in preventing ETEC infection.

In the developing world, the incidence of diarrhoea varies greatly by place, season, and even by year independent of season. Simultaneous studies in multiple sites in one country and studies over multiple years would determine the extent of this variability for ETEC infections, and would improve interpretation of existing data and planning of prevention and control programmes.

Finally, studies of relative frequency of diarrhoeagenic pathogens often do not include identification of *Campylobacter*, *Rotavirus*, EPEC or parasites, do not use highly sensitive PCR techniques for the identification of *Shigella*, and do not present results controlling for asymptomatic infections. Addressing these limitations in future studies will improve our understanding of the relative contribution of different pathogens to disease incidence.

The major data needs regarding mortality and complications from ETEC infections are:

- determination of the economic and social burden due to ETEC infections and mortality;
- calculation of CFRs and mortality rates in population-based studies;
- rates of complications in population-based studies of ETEC infection;

- further studies of frequency of moderate or severe dehydration in adults compared to children and the reasons for any differences;
- studies of long-term complications of ETEC infections, including physical fitness, language ability and cognitive function.

Data on complications and mortality due to ETEC infections is extremely limited, and is generally limited to facility-based studies. Calculation of age-specific case-fatality and complication rates may be achieved by studying a discrete number of health facilities providing care for the majority of a given population, in conjunction with a simultaneous population-based incidence study. The clinical severity of ETEC infections is variable, depending both on the host as well as the bacterium and the specific CFs and toxins present, and such studies may improve the understanding of this variability. Such studies could also be done examining multiple pathogens simultaneously in order to minimize costs and provide data on the relative contribution of different pathogens to serious morbidity and mortality.

Data on long-term complications of ETEC infections is also lacking, and longitudinal cohort studies can be conducted examining the relationship between the frequency and severity of multiple ETEC infections and long-term effects on physical, language and cognitive abilities.

The major data needs regarding preventive measures for ETEC infections are:

- further research into the immunology of natural protection from ETEC, as well as methods of vaccine delivery and optimal vaccine antigens;
- effect of vitamin A and zinc deficiency or supplementation on risk of severe ETEC infections;
- determination of proportion of ETEC infections attributable to different routes of transmission in different settings;
- evaluation of the cost-effectiveness and sustainability of large scale introduction of non-vaccine preventive measures in endemic settings, and the feasibility of rapid introduction of non-vaccine preventive measures in epidemic settings.

Such research is critical to define the most effective prevention measures. Research also needs to continue on cost-effective, sustainable, large-scale models for implementation of more general

prevention strategies, such as provision of safe food and water.

The major needs regarding diagnostics for ETEC infections are:

- standardization of the molecular definition of ETEC, based on either PCR or DNA probes for enterotoxins, for surveillance purposes;
- evaluation of the performance of PCR compared to ELISA for toxin identification;
- development of correction factors for other diagnostic methods to enable comparison of incidence results.

Existing data regarding the epidemiology of ETEC infections rests on the quality and consistency of diagnostic methods. In order to be able to compare results from different studies, a standardized molecular definition of ETEC for surveillance purposes is urgently needed. Moreover, because different diagnostic methods are available in different sites, correction factors for different diagnostic methods need to be developed to allow comparison of results to the gold standard. An international microbiological standard, along with a centralized system of laboratory training and quality assurance, would form the foundation for addressing the other data gaps.

Although much is known about the burden of ETEC infections, there are still substantial gaps in knowledge, including large geographic areas and important age groups. Filling in these gaps will require extensive planning and investment, but studies can simultaneously fill in similar gaps for other important infectious causes of diarrhoea. This information is essential in order to direct research into effective interventions, and to target the interventions for maximum impact.

ACKNOWLEDGEMENTS

This work was supported in part by the U.S. National Institutes of Health Fogarty International Center and by grant number 32143 from the Bill and Melinda Gates Foundation 'Assessment of diarrhoea disease burden and public health programs to control diarrhoea in Asian subcontinent and Africa'.

DECLARATION OF INTEREST

None.

REFERENCES

1. Wenneras C, Erling V. Prevalence of enterotoxigenic *Escherichia coli*-associated diarrhoea and carrier state in the developing world. *Journal of Health, Population and Nutrition* 2004; **22**: 370–382.
2. Anon. Development of vaccines against cholera and diarrhoea due to enterotoxigenic *Escherichia coli*: memorandum from a WHO meeting. *Bulletin of the World Health Organization* 1990; **68**: 303–312.
3. Boedeker EC. Vaccines for enterotoxigenic *Escherichia coli*: current status. *Current Opinions in Gastroenterology* 2004; **21**: 15–19.
4. Levine MM, *et al.* Immunity to enterotoxigenic *Escherichia coli*. *Infection and Immunity* 1979; **23**: 729–736.
5. Gothefors L, *et al.* Presence of colonization factor antigens on fresh isolates of fecal *Escherichia coli*: a prospective study. *Journal of Infectious Disease* 1985; **152**: 1128–1133.
6. Katouli M, *et al.* Occurrence of colonization factor antigens I & II in enterotoxigenic *Escherichia coli* associated diarrhoea in Iran & correlation with severity of disease. *Indian Journal of Medical Research* 1992; **95**: 115–120.
7. Heyman DL (ed.). *Control of Communicable Diseases Manual*, 18th edn. Washington, DC: American Public Health Association, 2004.
8. Mattila L, *et al.* Short-term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebo-controlled study during two seasons. *Clinical Infectious Diseases* 1993; **17**: 779–782.
9. Chakraborty S, *et al.* Concomitant infection of enterotoxigenic *Escherichia coli* in an outbreak of cholera caused by *Vibrio cholerae* O1 and O139 in Ahmedabad, India. *Journal of Clinical Microbiology* 2001; **39**: 3241–3246.
10. Dalton CB, *et al.* Outbreaks of enterotoxigenic *Escherichia coli* infection in American adults: a clinical and epidemiologic profile. *Epidemiology & Infection* 1999; **123**: 9–16.
11. Porat N, *et al.* Prevalence of intestinal infections caused by diarrheagenic *Escherichia coli* in Bedouin infants and young children in Southern Israel. *Pediatric Infectious Disease Journal* 1998; **17**: 482–488.
12. Steinsland H, *et al.* Enterotoxigenic *Escherichia coli* infections and diarrhea in a cohort of young children in Guinea-Bissau. *Journal of Infectious Diseases* 2002; **186**: 1740–1747.
13. Nishikawa Y, *et al.* Epidemiology and properties of heat-stable enterotoxin-producing *Escherichia coli* serotype O169:H41. *Epidemiology & Infection* 1998; **121**: 31–42.
14. Steinsland H, *et al.* Development and evaluation of genotypic assays for the detection and characterization of enterotoxigenic *Escherichia coli*. *Diagnostic Microbiology & Infectious Disease* 2003; **45**: 97–105.
15. Long KZ, *et al.* Proportional hazards analysis of diarrhea due to enterotoxigenic *Escherichia coli* and breast feeding in a cohort of urban Mexican children.

- American Journal of Epidemiology* 1994; **139**: 193–205.
16. **Brussow H, Rahim H, Freire W.** Epidemiological analysis of serologically determined rotavirus and enterotoxigenic *Escherichia coli* infections in Ecuadorian children. *Journal of Clinical Microbiology* 1992; **30**: 1585–1587.
 17. **Qadri F, et al.** Enterotoxigenic *Escherichia coli* and *Vibrio cholerae* diarrhea, Bangladesh, 2004. *Emerging Infectious Diseases* 2005; **11**: 1266.
 18. **Abu-Elyazeed R, et al.** Epidemiology of enterotoxigenic *Escherichia coli* diarrhea in a pediatric cohort in a periurban area of lower Egypt. *Journal of Infectious Diseases* 1999; **179**: 382–389.
 19. **Rao MR, et al.** High disease burden of diarrhea due to enterotoxigenic *Escherichia coli* among rural Egyptian infants and young children. *Journal of Clinical Microbiology* 2003; **41**: 4862–4864.
 20. **Valentiner-Branth P, et al.** Cohort study of Guinean children: incidence, pathogenicity, conferred protection, and attributable risk for enteropathogens during the first 2 years of life. *Journal of Clinical Microbiology* 2003; **41**: 4238–4245.
 21. **Bhan MK, et al.** Descriptive epidemiology of persistent diarrhoea among young children in rural northern India. *Bulletin of the World Health Organization* 1989; **67**: 281–288.
 22. **Tin A, et al.** Epidemiology and aetiology of acute childhood diarrhoea in Burma: a rural community survey. *Transactions of the Royal Society of Tropical Medicine & Hygiene* 1989; **83**: 827–830.
 23. **Varavithya W, et al.** Importance of salmonellae and *Campylobacter jejuni* in the etiology of diarrheal disease among children less than 5 years of age in a community in Bangkok, Thailand. *Journal of Clinical Microbiology* 1990; **28**: 2507–2510.
 24. **Punyaratabandhu P, et al.** Childhood diarrhoea in a low-income urban community in Bangkok: incidence, clinical features, and child caretaker's behaviours. *Journal of Diarrhoeal Disease Research* 1991; **9**: 244–249.
 25. **Chen KC, et al.** The epidemiology of diarrhoeal diseases in southeastern China. *Journal of Diarrhoeal Disease Research* 1991; **9**: 94–99.
 26. **Orndorff GR, et al.** Enterotoxigenic *Escherichia coli* diarrhea in children less than five years of age in central Java. *American Journal of Tropical Medicine & Hygiene* 1996; **55**: 449–451.
 27. **Richie E, et al.** Enterotoxigenic *Escherichia coli* diarrhea among young children in Jakarta, Indonesia. *American Journal of Tropical Medicine & Hygiene* 1997; **57**: 85–90.
 28. **Isenbarger DW, et al.** Prospective study of the incidence of diarrhoea and prevalence of bacterial pathogens in a cohort of Vietnamese children along the Red River. *Epidemiology & Infection* 2001; **127**: 229–236.
 29. **Giugliano LG, et al.** Longitudinal study of diarrhoeal disease in a peri-urban community in Manaus (Amazon-Brazil). *Annals of Tropical Medicine & Parasitology* 1986; **80**: 443–450.
 30. **Schorling JB, et al.** A prospective study of persistent diarrhea among children in an urban Brazilian slum. Patterns of occurrence and etiologic agents. *American Journal of Epidemiology* 1990; **132**: 144–156.
 31. **Paniagua M, et al.** Analysis of incidence of infection with enterotoxigenic *Escherichia coli* in a prospective cohort study of infant diarrhea in Nicaragua. *Journal of Clinical Microbiology* 1997; **35**: 1404–1410.
 32. **Black RE, et al.** Incidence and etiology of infantile diarrhea and major routes of transmission in Huascar, Peru. *American Journal of Epidemiology* 1989; **129**: 785–799.
 33. **Adkins HJ, et al.** Two-year survey of etiologic agents of diarrheal disease at San Lazaro Hospital, Manila, Republic of the Philippines. *Journal of Clinical Microbiology* 1987; **25**: 1143–1147.
 34. **Lindblom GB, et al.** *Campylobacter jejuni/coli* and enterotoxigenic *Escherichia coli* (ETEC) in faeces from children and adults in Tanzania. *Scandinavian Journal of Infectious Diseases* 1995; **27**: 589–593.
 35. **Casalino M, et al.** A two-year study of enteric infections associated with diarrhoeal diseases in children in urban Somalia. *Transactions of the Royal Society of Tropical Medicine & Hygiene* 1988; **82**: 637–641.
 36. **Gomes TA, et al.** Enteropathogens associated with acute diarrheal disease in urban infants in Sao Paulo, Brazil. *Journal of Infectious Diseases* 1991; **164**: 331–337.
 37. **Qadri F, et al.** Prevalence of toxin types and colonization factors in enterotoxigenic *Escherichia coli* isolated during a 2-year period from diarrheal patients in Bangladesh. *Journal of Clinical Microbiology* 2000; **38**: 27–31.
 38. **Echeverria P, et al.** Identification by DNA hybridization of enterotoxigenic *Escherichia coli* in a longitudinal study of villages in Thailand. *Journal of Infectious Disease* 1985; **151**: 124–130.
 39. **Baqi AH, et al.** Surveillance of patients attending a rural diarrhoea treatment centre in Bangladesh. *Tropical & Geographical Medicine* 1991; **43**: 17–22.
 40. **Albert MJ, et al.** Case-control study of enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. *Journal of Clinical Microbiology* 1999; **37**: 3458–3464.
 41. **Albert MJ, et al.** Controlled study of *Escherichia coli* diarrheal infections in Bangladeshi children. *Journal of Clinical Microbiology* 1995; **33**: 973–977.
 42. **Khan MM, et al.** Aetiologic agents of diarrhoeal diseases in hospitalised children in Rawalpindi, Pakistan. *Journal of Diarrhoeal Disease Research* 1988; **6**: 228–231.
 43. **Yamashiro T, et al.** Etiological study of diarrheal patients in Vientiane, Lao People's Democratic Republic. *Journal of Clinical Microbiology* 1998; **36**: 2195–2199.
 44. **Subekti DS, et al.** Prevalence of enterotoxigenic *Escherichia coli* (ETEC) in hospitalized acute diarrhea patients in Denpasar, Bali, Indonesia. *Diagnostic Microbiology & Infectious Disease* 2003; **47**: 399–405.

45. **Ram PK, et al.** Part II. Analysis of data gaps pertaining to *Shigella* infections in low and medium human development index countries, 1984–2005. *Epidemiology & Infection*. doi: 10.1017/S0950268807009351.
46. **Crump JA, et al.** Part I. Analysis of data gaps pertaining to *Salmonella enterica* serotype Typhi infections in low and medium human development index countries, 1984–2005. *Epidemiology & Infection*. doi: 10.1017/S0950268807009338.
47. **Huilan S, et al.** Etiology of acute diarrhoea among children in developing countries: a multicentre study in five countries. *Bulletin of the World Health Organization* 1991; **69**: 549–555.
48. **Qadri F, et al.** Enterotoxigenic *Escherichia coli* in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. *Clinical Microbiology Reviews* 2005; **18**: 465–483.
49. **Kulshrestha SB, et al.** Enterotoxigenic *Escherichia coli* from an outbreak with choleric syndromes of gastroenteritis. *Journal of Communicable Diseases* 1989; **21**: 313–317.
50. **Taneja N, et al.** Nosocomial outbreak of diarrhoea by enterotoxigenic *Escherichia coli* among preterm neonates in a tertiary care hospital in India: pitfalls in healthcare. *Journal of Hospital Infection* 2003; **53**: 193–197.
51. **Black RE, Brown KH, Becker S.** Effects of diarrhea associated with specific enteropathogens on the growth of children in rural Bangladesh. *Pediatrics* 1984; **73**: 799–805.
52. **Guerrant DI, et al.** Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four–seven years later in a poor urban community in northeast Brazil. *American Journal of Tropical Medicine & Hygiene* 1999; **61**: 707–713.
53. **Kosek M, Bern C, Guerrant RL.** The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. *Bulletin of the World Health Organization* 2003; **81**: 197–204.
54. **Youssef M, et al.** Bacterial, viral and parasitic enteric pathogens associated with acute diarrhea in hospitalized children from northern Jordan. *FEMS Immunology & Medical Microbiology* 2000; **28**: 257–263.
55. **Wolf MK.** Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic *Escherichia coli*. *Clinical Microbiology Reviews* 1997; **10**: 569–584.
56. **Peruski L, et al.** Phenotypic diversity of enterotoxigenic *Escherichia coli* strains from a community-based study of pediatric diarrhea in periurban Egypt. *Journal of Clinical Microbiology* 1999; **37**: 2974–2978.
57. **Rivas M, et al.** Antibody responses against *Escherichia coli* heat-labile toxin and colonization factor antigens I and II in Argentinian children. *Journal of Infectious Diseases* 1045; **171**: 1045–1049.
58. **Clemens J, et al.** Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic *Escherichia coli*: results of a large-scale field trial. *Journal of Infectious Diseases* 1988; **158**: 372–377.
59. **Steinland H, et al.** Protection from natural infections with enterotoxigenic *Escherichia coli*: longitudinal study. *Lancet* 2003; **362**: 286–291.
60. **Clemens J, et al.** Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic *Escherichia coli* in Egypt: application of an evidence-based method. *Journal of Infectious Diseases* 2004; **189**: 2299–2307.
61. **WHO.** Future directions for research on enterotoxigenic *Escherichia coli* vaccines for developing countries. *Weekly Epidemiological Record* 2006; **81**: 97–104.
62. **Black RE, Brown KH, Becker S.** Malnutrition is a determining factor in diarrheal duration, but not incidence, among young children in a longitudinal study in rural Bangladesh. *American Journal of Clinical Nutrition* 1984; **39**: 87–94.
63. **Black RE, et al.** Nutritional status, body size and severity of diarrhoea associated with rotavirus or enterotoxigenic *Escherichia coli*. *Journal of Tropical Medicine & Hygiene* 1984; **87**: 83–89.
64. **Clemens JD, et al.** Breastfeeding and the risk of life-threatening enterotoxigenic *Escherichia coli* diarrhea in Bangladeshi infants and children. *Pediatrics* 1997; **100**: E2.
65. **Long KZ, et al.** The impact of infant feeding patterns on infection and diarrheal disease due to enterotoxigenic *Escherichia coli*. *Salud Publica de Mexico* 1999; **41**: 263–270.
66. **Khin New O, Sebastian AA, Aye T.** Carriage of enteric bacterial pathogens by house flies in Yangon, Myanmar. *Journal of Diarrhoeal Disease Research* 1989; **7**: 81–84.
67. **Daniels NA, et al.** Traveler's diarrhea at sea: three outbreaks of waterborne enterotoxigenic *Escherichia coli* on cruise ships. *Journal of Infectious Diseases* 2000; **181**: 1491–1495.
68. **Qadri F, et al.** Enterotoxigenic *Escherichia coli* and *Vibrio cholerae* diarrhea, Bangladesh, 2004. *Emerging Infectious Diseases* 2004; **11**: 1104–1107.
69. **Katouli M, et al.** Aetiological studies of diarrhoeal diseases in infants and young children in Iran. *Journal of Tropical Medicine & Hygiene* 1990; **93**: 22–27.
70. **Echeverria P, et al.** Case-control study of endemic diarrheal disease in Thai children. *Journal of Infectious Diseases* 1989; **159**: 543–548.
71. **Mackenzie MK, et al.** Aetiology of diarrhoea in adequately nourished young African children in Durban, South Africa. *Annals of Tropical Paediatrics* 1984; **4**: 183–187.
72. **Moyenuddin M, Rahman KM, Sack DA.** The aetiology of diarrhoea in children at an urban hospital in Bangladesh. *Transactions of the Royal Society of Tropical Medicine & Hygiene* 1987; **81**: 299–302.
73. **Okeke IN, et al.** Characterization of *Escherichia coli* strains from cases of childhood diarrhea in provincial

- southwestern Nigeria. *Journal of Clinical Microbiology* 2000; **38**: 7–12.
74. **Ming ZF, et al.** Diarrhoeal disease in children less than one year of age at a children's hospital in Guangzhou, People's Republic of China. *Transactions of the Royal Society of Tropical Medicine & Hygiene* 1991; **85**: 667–669.
 75. **Regua-Mangia AH, et al.** Frequency and characteristics of diarrhoeagenic *Escherichia coli* strains isolated from children with and without diarrhoea in Rio de Janeiro, Brazil. *Journal of Infection* 2004; **48**: 161–167.
 76. **Goh Rowland SG, et al.** The etiology of diarrhoea studied in the community in young urban Gambian children. *Journal of Diarrhoeal Diseases Research* 1985; **3**: 7–13.
 77. **Sang FC, et al.** *Escherichia coli* associated with acute measles and diarrhoea at Kenyatta National Hospital, Kenya. *East African Medical Journal* 1992; **69**: 135–139.
 78. **Ogunsanya TI, Rotimi VO, Adenuga A.** A study of the aetiological agents of childhood diarrhoea in Lagos, Nigeria. *Journal of Medical Microbiology* 1994; **40**: 10–14.
 79. **Sarinho SW, et al.** A study of the importance of the enterotoxigenic *E. coli* in children with acute diarrhoea in Recife, Brazil. *Journal of Tropical Pediatrics* 1993; **39**: 304–306.
 80. **Mikhail IA, et al.** Epidemiology of bacterial pathogens associated with infectious diarrhea in Djibouti. *Journal of Clinical Microbiology* 1990; **28**: 956–961.
 81. **Gascon J, et al.** Diarrhea in children under 5 years of age from Ifakara, Tanzania: a case-control study. *Journal of Clinical Microbiology* 2000; **38**: 4459–4462.
 82. **Oyfo BA, et al.** Toxins and colonization factor antigens of enterotoxigenic *Escherichia coli* among residents of Jakarta, Indonesia. *American Journal of Tropical Medicine & Hygiene* 2001; **65**: 120–124.
 83. **Kain KC, et al.** Etiology of childhood diarrhea in Beijing, China. *Journal of Clinical Microbiology* 1991; **29**: 90–95.
 84. **Germani Y, et al.** Survey in Vanuatu on enterotoxigenic *Escherichia coli* in children and infants with and without acute diarrhea. *Journal of Clinical Microbiology* 1985; **21**: 630–633.
 85. **Akinyemi KO, et al.** *Escherichia coli* in patients with acute gastroenteritis in Lagos, Nigeria. *East African Medical Journal* 1998; **75**: 512–515.
 86. **Sen D, et al.** Studies on *Escherichia coli* as a cause of acute diarrhoea in Calcutta. *Journal of Medical Microbiology* 1984; **17**: 53–58.
 87. **Echeverria P, et al.** A comparative study of enterotoxigenic *Escherichia coli*, *Shigella*, *Aeromonas*, and *Vibrio* as etiologies of diarrhea in northeastern Thailand. *American Journal of Tropical Medicine & Hygiene* 1985; **34**: 547–554.
 88. **Katouli M, Jaafari A, Ketabi GR.** The role of diarrhoeagenic *Escherichia coli* in acute diarrhoeal diseases in Bandar-Abbas, Iran. *Journal of Medical Microbiology* 1988; **27**: 71–74.
 89. **Echeverria P, et al.** Etiology of diarrhea in a rural community in western Thailand: importance of enteric viruses and enterovirulent *Escherichia coli*. *Journal of Infectious Disease* 1994; **169**: 916–919.
 90. **Faruque AS, et al.** Aetiological, clinical and epidemiological characteristics of a seasonal peak of diarrhoea in Dhaka, Bangladesh. *Scandinavian Journal of Infectious Diseases* 1998; **30**: 393–396.
 91. **Begue RE, et al.** Diarrheal disease in Peru after the introduction of cholera. *American Journal of Tropical Medicine & Hygiene* 1994; **51**: 585–589.
 92. **Ghosh AR, et al.** Enterotoxigenic *Escherichia coli* associated diarrhoea among infants aged less than six months in Calcutta, India. *European Journal of Epidemiology* 1996; **12**: 81–84.
 93. **Geyer A, et al.** The microbial aetiology of summer paediatric gastroenteritis at Ga-Rankuwa Hospital in South Africa. *East African Medical Journal* 1993; **70**: 78–81.
 94. **Khan MU, et al.** Cholera, rotavirus and ETEC diarrhoea: some clinico-epidemiological features. *Transactions of the Royal Society of Tropical Medicine & Hygiene* 1988; **82**: 485–488.
 95. **Bhan MK, et al.** Enteroaggregative *Escherichia coli* associated with persistent diarrhea in a cohort of rural children in India. *Journal of Infectious Disease* 1989; **159**: 1061–1064.
 96. **Abbar F, Khalef S, Yonis D.** A prospective study of some diarrhoeagenic *Escherichia coli* in infants with diarrhoea in Mosul, Iraq. *Annals of Tropical Paediatrics* 1991; **11**: 99–102.
 97. **Faruque AS, et al.** Common diarrhea pathogens and the risk of dehydration in young children with acute watery diarrhea: a case-control study. *American Journal of Tropical Medicine & Hygiene* 1993; **49**: 93–100.
 98. **Mikhail IA, et al.** Microbiologic and clinical study of acute diarrhea in children in Aswan, Egypt. *Scandinavian Journal of Infectious Disease* 1989; **21**: 59–65.
 99. **Echeverria P, et al.** Identification by DNA hybridisation of enterotoxigenic *Escherichia coli* in homes of children with diarrhoea. *Lancet* 1984; **1**: 63–66.
 100. **Rasrinaul L, et al.** Foods as a source of enteropathogens causing childhood diarrhea in Thailand. *American Journal of Tropical Medicine & Hygiene* 1988; **39**: 97–102.
 101. **Subekti D, et al.** Enterotoxigenic *Escherichia coli* and other causes of infectious pediatric diarrheas in Jakarta, Indonesia. *Southeast Asian Journal of Tropical Medicine & Public Health* 1993; **24**: 420–424.
 102. **Ise T, et al.** Clinical evaluation and bacterial survey in infants and young children with diarrhoea in the Santa Cruz district, Bolivia. *Journal of Tropical Pediatrics* 1994; **40**: 369–374.
 103. **Tornieporth NG, et al.** Differentiation of pathogenic *Escherichia coli* strains in Brazilian children by PCR. *Journal of Clinical Microbiology* 1995; **33**: 1371–1374.
 104. **Begaud E, et al.** Detection of diarrhoeagenic *Escherichia coli* in children less than ten years old with and without

- diarrhea in New Caledonia using seven acetylaminofluorene-labeled DNA probes. *American Journal of Tropical Medicine & Hygiene* 1993; **48**: 26–34.
105. **Ratchtrachenchai OA, et al.** Prevalence of childhood diarrhoea-associated *Escherichia coli* in Thailand. *Journal of Medical Microbiology* 2004; **53**: 237–243.
106. **Georges MC, et al.** Parasitic, bacterial, and viral enteric pathogens associated with diarrhea in the Central African Republic. *Journal of Clinical Microbiology* 1984; **19**: 571–575.
107. **Zaki AM, et al.** The detection of enteropathogens in acute diarrhea in a family cohort population in rural Egypt. *American Journal of Tropical Medicine & Hygiene* 1986; **35**: 1013–1022.